Business Update

Meridian Bioscience produces clinical respiratory syncytial virus for human clinical trials

Published in Hospital Business Week, February 4th, 2007

Meridian Bioscience, Inc., Cincinnati, Ohio (VIVO) announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS), formerly Viral Antigens, Inc., completed manufacturing of a clinical infectious inoculum of respiratory syncytial virus (RSV) in its biopharmaceutical facility located in Memphis, Tennessee.

The RSV clinical material will be used by a contract biopharmaceutical client to conduct human challenge studies in order to establish optimal infectious levels in healthy adult volunteers. The client, Alnylam Pharmaceuticals, has commenced a clinical program to evaluate the anti-viral activity of its therapeutic product for treatment of RSV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2007-02-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry